Boston Scientific Raises 2022 Sales Guidance

By Will Feuer

Boston Scientific Corp. raised its full-year sales guidance, but lowered its expectations for 2022 earnings.

The Marlborough, Mass.-based medical-device maker said it now expects reported sales to rise between 7% and 9% for the year, up from its previously issued guidance of 6% to 8% growth.

Organic sales, which exclude the impact of currency adjustments and divestitures, are now expected to rise 6.5% to 8.5%. Boston Scientific previously said it expected organic sales growth of 6% to 8%.

The company also said it now expects earnings to be between 78 cents a share and 88 cents a share, down from its prior guidance of 94 cents a share to $1.04 a share.

The company also narrowed its adjusted earnings guidance to between $1.74 a share and $1.79 a share, from its prior guidance of $1.73 a share to $1.79 cents a share.

Write to Will Feuer at Will.Feuer@wsj.com

(END) Dow Jones Newswires

April 27, 2022 07:08 ET (11:08 GMT)

Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Aug 2024 to Sep 2024